Ayumu Taguchi1, Samir Hanash, Andrew Rundle, Ian W McKeague, Deliang Tang, Salima Darakjy, J Michael Gaziano, Howard D Sesso, Frederica Perera. 1. Authors' Affiliations: Department of Clinical Cancer Prevention, University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Epidemiology, Biostatistics, and Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York, New York; Divisions of Preventive Medicine and Aging, Department of Medicine, Brigham and Women's Hospital; and Boston VA Medical Center, Boston, Massachusetts.
Abstract
BACKGROUND: Our prior studies of lung cancer suggested that a novel biomarker (pro-surfactant protein B or pro-SFTPB) might serve as a predictive marker for this disease. We aimed to determine the potential use of pro-SFTPB for distinguishing lung cancer cases from matched controls as a risk marker. METHODS:Study subjects were drawn from the longitudinal Physicians' Health Study (PHS). Cases (n = 188) included individuals who were cancer-free at study enrollment but developed lung cancer during follow-up. Controls (n = 337) were subjects who did not develop lung cancer. Cases and controls were matched on date of study enrollment, age at enrollment, and smoking status and amount. Baseline plasma samples drawn at enrollment were analyzed for pro-SFTPB using ELISA to detect differences in protein expression levels for cases and controls. RESULTS:Pro-SFTPB nondetectable status was significantly associated with lung cancer risk [OR = 5.88; 95% confidence interval (CI) 1.24-27.48]. Among subjects with detectable levels of the protein, increasing plasma concentration of pro-SFTPB was associated with higher lung cancer risk (OR = 1.41 per unit increase in log pro-SFTPB; 95% CI 1.08-1.84). CONCLUSION: These results suggest a nonlinear, J-shaped association between plasma pro-SFTPB levels and lung cancer risk, with both nondetectable and higher levels of the marker being associated with lung cancer. IMPACT: These results show promise of a risk marker that could contribute to predicting risk for lung cancer development and to narrowing the high-risk population for low-dose computed tomography screening.
RCT Entities:
BACKGROUND: Our prior studies of lung cancer suggested that a novel biomarker (pro-surfactant protein B or pro-SFTPB) might serve as a predictive marker for this disease. We aimed to determine the potential use of pro-SFTPB for distinguishing lung cancer cases from matched controls as a risk marker. METHODS: Study subjects were drawn from the longitudinal Physicians' Health Study (PHS). Cases (n = 188) included individuals who were cancer-free at study enrollment but developed lung cancer during follow-up. Controls (n = 337) were subjects who did not develop lung cancer. Cases and controls were matched on date of study enrollment, age at enrollment, and smoking status and amount. Baseline plasma samples drawn at enrollment were analyzed for pro-SFTPB using ELISA to detect differences in protein expression levels for cases and controls. RESULTS: Pro-SFTPB nondetectable status was significantly associated with lung cancer risk [OR = 5.88; 95% confidence interval (CI) 1.24-27.48]. Among subjects with detectable levels of the protein, increasing plasma concentration of pro-SFTPB was associated with higher lung cancer risk (OR = 1.41 per unit increase in log pro-SFTPB; 95% CI 1.08-1.84). CONCLUSION: These results suggest a nonlinear, J-shaped association between plasma pro-SFTPB levels and lung cancer risk, with both nondetectable and higher levels of the marker being associated with lung cancer. IMPACT: These results show promise of a risk marker that could contribute to predicting risk for lung cancer development and to narrowing the high-risk population for low-dose computed tomography screening.
Authors: Timothy Driscoll; Deborah Imel Nelson; Kyle Steenland; James Leigh; Marisol Concha-Barrientos; Marilyn Fingerhut; Annette Prüss-Ustün Journal: Am J Ind Med Date: 2005-12 Impact factor: 2.214
Authors: K E Greene; J R Wright; K P Steinberg; J T Ruzinski; E Caldwell; W B Wong; W Hull; J A Whitsett; T Akino; Y Kuroki; H Nagae; L D Hudson; T R Martin Journal: Am J Respir Crit Care Med Date: 1999-12 Impact factor: 21.405
Authors: Ralph Epaud; Machiko Ikegami; Jeffrey A Whitsett; Alan H Jobe; Timothy E Weaver; Henry T Akinbi Journal: Am J Respir Cell Mol Biol Date: 2003-03 Impact factor: 6.914
Authors: Angela Haczku; Elena N Atochina; Yaniv Tomer; Yang Cao; Colleen Campbell; Seth T Scanlon; Scott J Russo; Goran Enhorning; Michael F Beers Journal: Am J Physiol Lung Cell Mol Physiol Date: 2002-10 Impact factor: 5.464
Authors: Richard Wender; Elizabeth T H Fontham; Ermilo Barrera; Graham A Colditz; Timothy R Church; David S Ettinger; Ruth Etzioni; Christopher R Flowers; G Scott Gazelle; Douglas K Kelsey; Samuel J LaMonte; James S Michaelson; Kevin C Oeffinger; Ya-Chen Tina Shih; Daniel C Sullivan; William Travis; Louise Walter; Andrew M D Wolf; Otis W Brawley; Robert A Smith Journal: CA Cancer J Clin Date: 2013-01-11 Impact factor: 508.702
Authors: C H Hennekens; J E Buring; J E Manson; M Stampfer; B Rosner; N R Cook; C Belanger; F LaMotte; J M Gaziano; P M Ridker; W Willett; R Peto Journal: N Engl J Med Date: 1996-05-02 Impact factor: 91.245
Authors: Johannes F Fahrmann; Tracey Marsh; Ehsan Irajizad; Nikul Patel; Eunice Murage; Jody Vykoukal; Jennifer B Dennison; Kim-Anh Do; Edwin Ostrin; Margaret R Spitz; Stephen Lam; Sanjay Shete; Rafael Meza; Martin C Tammemägi; Ziding Feng; Samir M Hanash Journal: J Clin Oncol Date: 2022-01-07 Impact factor: 44.544
Authors: William R Wikoff; Samir Hanash; Brian DeFelice; Suzanne Miyamoto; Matt Barnett; Yang Zhao; Gary Goodman; Ziding Feng; David Gandara; Oliver Fiehn; Ayumu Taguchi Journal: J Clin Oncol Date: 2015-08-17 Impact factor: 44.544
Authors: Florence Guida; Nan Sun; Leonidas E Bantis; David C Muller; Peng Li; Ayumu Taguchi; Dilsher Dhillon; Deepali L Kundnani; Nikul J Patel; Qingxiang Yan; Graham Byrnes; Karel G M Moons; Anne Tjønneland; Salvatore Panico; Claudia Agnoli; Paolo Vineis; Domenico Palli; Bas Bueno-de-Mesquita; Petra H Peeters; Antonio Agudo; Jose M Huerta; Miren Dorronsoro; Miguel Rodriguez Barranco; Eva Ardanaz; Ruth C Travis; Karl Smith Byrne; Heiner Boeing; Annika Steffen; Rudolf Kaaks; Anika Hüsing; Antonia Trichopoulou; Pagona Lagiou; Carlo La Vecchia; Gianluca Severi; Marie-Christine Boutron-Ruault; Torkjel M Sandanger; Elisabete Weiderpass; Therese H Nøst; Kostas Tsilidis; Elio Riboli; Kjell Grankvist; Mikael Johansson; Gary E Goodman; Ziding Feng; Paul Brennan; Mattias Johansson; Samir M Hanash Journal: JAMA Oncol Date: 2018-10-11 Impact factor: 31.777
Authors: L Renee Ruhaak; Carol Stroble; Jianliang Dai; Matt Barnett; Ayumu Taguchi; Gary E Goodman; Suzanne Miyamoto; David Gandara; Ziding Feng; Carlito B Lebrilla; Samir Hanash Journal: Cancer Prev Res (Phila) Date: 2016-01-26